Eli Rothenberg
Professor of Biochemistry, Molecular Pharmacology, Biomedical Engineering & Director, Single-Molecule Biophotonics NYU Langone Health
Seminars
Wednesday 28th January 2026
A New Precision Framework for PARP and DDR Inhibitors: Mechanistic Measurement, HRD Modeling & Translational Impact
9:45 am
- Unveiling a new generation of precision tools, mechanistic assays, and cellular models that directly measure PARP1 dynamics, replication-fork instability, and DDR pathway engagement—capabilities not accessible with current preclinical platforms.
- Revealing distinct mechanistic modes of PARP inhibitor action and toxicity —a PARP1-retention–driven and a context-specific signalling — providing a mechanistic roadmap for which tumors respond, why resistance emerges, and how to rationally target each context.
- Delivering predictive, high-resolution models of PARPi response across BRCA and non-BRCA tumors, identifying actionable and differential biomarkers for HRDs, combination opportunities, and mechanistic vulnerabilities that can immediately feed into drug discovery and translational programs.
- Defining a new precision-medicine framework for DDR therapeutics and beyond, enabling industry partners to design better molecules, more informative functional screens, mechanistically aligned dosing strategies, and clinically meaningful patient-selection criteria.
